Protocols to Assess the Gastrointestinal Side Effects Resulting from Inhibition of Cyclo-Oxygenase Isoforms
Author:
Whittle Brendan J. R.
Reference30 articles.
1. García Rodríguez LA, Barreales Tolosa L (2007) Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132:498–506
2. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124:288–292
3. Whittle BJR (2003) Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17:301–313
4. Wallace JL, McKnight W, Reuter B, Vergnolle N (2000) NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119:705–714
5. Lichtenberger LM, Romero JJ, Dial EJ (2007) Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 150:913–919